Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (ifcg) Regimen for Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV and Without TP53 Aberrations
Nitin Jain,Philip Thompson,Jan Burger,Alessandra Ferrajoli,Koichi Takahashi,Zeev Estrov,Gautam Borthakur,Prithviraj Bose,Tapan Kadia,Naveen Pemmaraju,Koji Sasaki,Marina Konopleva,Elias Jabbour,Naveen Garg,Xuemei Wang,Rashmi Kanagal-Shamanna,Keyur Patel,Wei Wang,Jeffrey Jorgensen,Sa Wang,Wanda Lopez,Ana Ayala,William Plunkett,Varsha Gandhi,Hagop Kantarjian,Susan O’Brien,Michael Keating,William G. Wierda
DOI: https://doi.org/10.1038/s41375-021-01280-8
2021-01-01
Leukemia
Abstract:Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mutated IGHV and absence of del(17p)/TP53 mutation. Patients received ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for three cycles. Patients who achieved complete remission (CR)/CR with incomplete count recvoery (CRi) with marrow undetectable measurable residual disease (U-MRD) received additional nine cycles of ibrutinib with three cycles of obinutuzumab; all others received nine additional cycles of ibrutinib and obinutuzumab. Patients in marrow U-MRD remission after cycle 12 discontinued all treatment, including ibrutinib. Forty-five patients were treated. The median follow-up is 41.3 months. Among the total 45 treated patients, after three cycles, 38% achieved CR/CRi and 87% achieved marrow U-MRD. After cycle 12, the corresponding numbers were 67% and 91%, respectively. Overall, 44/45 (98%) patients achieved marrow U-MRD as best response. No patient had CLL progression. The 3-year progression-free survival (PFS) and overall survival (OS) were 98% and 98%, respectively. Per trial design, all patients who completed cycle 12 discontinued ibrutinib, providing for a time-limited therapy. Grade 3–4 neutropenia and thrombocytopenia occurred in 58% and 40% patients, respectively. The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation.